Actual stability depends on storage conditions, handling, and the researchers own risk profile
GLP-1s are already in limited supply for the patients that need them, and the projected drug prices of targeted therapies have raised questions for cost-effectiveness researchers
Tirzepatide targets many parts of the bodys metabolism
Discussion In this database study, treatment with semaglutide (against sitagliptin, a placebo proxy) led to a reduced risk of MACE, and tirzepatide (against dulaglutide) demonstrated a similar risk reduction in patients at elevated cardiovascular risk with obesity and type 2 diabetes
Second, compared to carbohydrate, the breakdown of fat takes substantially longer (Hargreaves and Spriet 2020)
GLP-1 does several important things